Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial (Q39091664)
Jump to navigation
Jump to search
scientific article published on 7 August 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial |
scientific article published on 7 August 2014 |
Statements
1 reference
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial (English)
1 reference
Kenneth W Mahaffey
1 reference
Matthew T Roe
1 reference
Robert A Harrington
1 reference
Pierluigi Tricoci
1 reference
Andreas Zeiher
1 reference
Deepak L Bhatt
1 reference
J Wouter Jukema
1 reference
Harvey White
1 reference
Lisa G Berdan
1 reference
Shaun G Goodman
1 reference
Tyrus Rorick
1 reference
Vera Bittner
1 reference
Corinne Hanotin
1 reference
Angèle Moryusef
1 reference
Robert Pordy
1 reference
William J Sasiela
1 reference
Jean-François Tamby
1 reference
Gregory G Schwartz
1 reference
Laurence Bessac
1 reference
Rafael Diaz
1 reference
Cheerag Shirodaria
1 reference
Michael Szarek
1 reference
7 August 2014
1 reference
1 reference
Identifiers
1 reference